SCHEMBL10072463

SCHEMBL10072463

[2H]C(C)[C@@]12CO[C@@H]([C@H](n3ccc(N)nc3=O)O1)[C@@H]2C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.41
THRB P10828 1/20 0.41
MTOR P42345 1/20 0.41
MDM2 Q00987 1/20 0.41
NCOA1 Q15788 1/20 0.41
NCOA3 Q9Y6Q9 1/20 0.41
PDE3A Q14432 3/20 0.38
CACNA1F O60840 2/20 0.38
ALB P02768 2/20 0.38
MAPT P10636 2/20 0.38
CACNA1D Q01668 2/20 0.38
CACNA1S Q13698 2/20 0.38
CACNA1C Q13936 2/20 0.38
PDE4D Q08499 1/20 0.37
SLC29A1 Q99808 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
NT5E P21589 1/20 0.35
TSHR P16473 1/20 0.33
GLA P06280 1/20 0.33
FGFR1 P11362 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12191308 0.82 LMNA (0.36) LMNATHRBMTORMDM2NCOA1
SCHEMBL10072466 0.80
SCHEMBL10072468 0.79 P2RY6 (0.39) SLC29A1
SCHEMBL10072462 0.78 ABL1 (0.50) LMNAMAPTNT5E
SCHEMBL1097293 0.78 LMNA (0.52) LMNATHRBMTORMDM2NCOA1
SCHEMBL2767893 0.78 LMNA (0.52) LMNATHRBMTORMDM2NCOA1
SCHEMBL5557391 0.78 LMNA (0.52) LMNATHRBMTORMDM2NCOA1
SCHEMBL19259067 0.78 LMNA (0.52) LMNATHRBMTORMDM2NCOA1
SCHEMBL24637965 0.76 LMNA (0.40) LMNATHRBMTORMDM2NCOA1
SCHEMBL15070507 0.76 LMNA (0.41) LMNATHRBMTORMDM2NCOA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130041144-A1 5'-SUBSTITUTED BICYCLIC NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM ISIS PHARMACEUTICALS, INC. (US) 2013-02-14 US disclosed
US-8268980-B2 5′-modified bicyclic nucleic acid analogs ISIS PHARMACEUTICALS, INC. (US) 2012-09-18 US disclosed
US-20120010393-A1 5'-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS ISIS PHARMACEUTICALS, INC. (US) 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130041144-A1 5'-SUBSTITUTED BICYCLIC NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM RNMT, HNRNPM, NOP2 LMNA 869/4885THRB 4400/4885MTOR 4062/4885
US-20120010393-A1 5'-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS NT5C3B, NSUN2, ADAR LMNA 203/4885THRB 4064/4885MTOR 3400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.